CeeNu Capsule
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
CeeNu Capsule contains lomustine, a nitrosourea alkylating agent used in cancer chemotherapy. Its labelling describes it for the treatment of certain types of brain tumours, given alone or with other medicines, and for Hodgkin’s lymphoma in patients whose disease has not responded to, or has worsened after, other therapy. It is taken by mouth under the supervision of an oncology team.
Product Information
The following description reflects information associated with lomustine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of certain types of brain tumours, alone or in combination with other medicines
- Described for Hodgkin’s lymphoma when other medicines have not worked or the disease has worsened
- Described as an alkylating agent that damages the DNA of rapidly dividing cells
Described Dosage & Administration
- Taken by mouth exactly as directed by the oncologist — the dose and interval set by the doctor should be followed
- Described as generally given as a single dose repeated only after an interval of several weeks, per prescribing information
- The stated dose should not be exceeded and doses should not be repeated early
Described Side Effects
Described side effects of lomustine-based chemotherapy include:
- Nausea and vomiting
- Loss of appetite
- Delayed lowering of blood cell counts (bone-marrow suppression), which the doctor monitors with blood tests
- Tiredness
Some effects are described as delayed and cumulative, so regular blood-count monitoring is described as required. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Full medical details, including all current medicines, should be shared with the doctor or healthcare team
- The doctor should be informed if the patient is pregnant or breastfeeding
- Regular blood-count monitoring is described as needed because effects on the bone marrow can be delayed
- Any persistent or severe side effect should be reviewed by the oncology team
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains lomustine and is used to treat certain brain tumours, alone or with other medicines, and Hodgkin’s lymphoma after other therapy has failed or the disease has worsened. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as taken by mouth under the supervision of an oncology team, generally as a single dose repeated only after an interval of several weeks. The dose and interval set by the doctor should be followed exactly.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.